WHO warns against use of remdesivir for COVID-19 patients

WHO warns against use of remdesivir for COVID-19 patients

The World Health Organisation (WHO) has warned that the anti-viral drug remdesivir should not be used for the treatment of hospitalised COVID-19 patients, arguing that trials have failed to prove that the treatment is effective.


WHO chief clinician Janet Diaz told a press conference in Geneva on Friday that there was no clear evidence that the use of remdesivir reduced the risk of death or the need for oxygen support.


Diaz said that there was no clear effect on the pace of recovery among trial patients.


Besides, the WHO said in a statement that the possibility that remdesivir caused harm could also not be ruled out.


In addition, there are “relatively high cost and resource implications associated with remdesivir,” the WHO argued, pointing out that the drug must be injected into the bloodstream.


The WHO had already published interim trial results in the middle of October that pointed to the drug’s lack of effectiveness.


However, the U.S. Food and Drug Administration formally approved remdesivir, a drug made by U.S. company Gilead Sciences, in October.


The drug has also won approval of the European Union (EU) for the treatment of severe cases of the disease caused by the novel coronavirus.


Anti-inflammatory steroids such as dexamethasone are the only known effective drugs used for severely ill Covid-19 patients.


“Right now we have one life-saving therapy,’’ Diaz said, stressing that the WHO has been strongly recommending steroids.


She added that use of oxygen, advanced respiratory therapies and good intensive care had also proven to be effective in helping coronavirus patients to survive.

Share this post